Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH <70 pg/ml. These results do not support the use of PAR to treat posttransplantation hyperparathyroidism.